BOTOX® vs. XEOMIN® for Chronic Migraine | MicrobiomeTrials← Back to trialsNCT05598723
BOTOX® vs. XEOMIN® for Chronic Migraine
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2023-02-24Est. Completion: 2027-02-24
Enrollment target: 128 participants Locations- Naval Medical Center Camp Lejeune, Jacksonville, North Carolina, United States
Other microbiome trials you might be interested in
Preventive Treatment of Migraine
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine …
Canoga Park, United StatesEst. completion Sep 12, 2028
Migraine
This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Spe…
Multiple Locations
The primary objective of the study is to evaluate the long-term safety and tolerability of subcutaneous fremanezumab in …
Aurora, United StatesCompleted Aug 15, 2025